Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 35.97% is in line with its 5-year average of 33.38%, near the high end of its 5-year range (-3.69%–46.55%).
0.40% below its 12-month average of 36.12%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 32.40%.
GROSS MARGIN
35.97%
GROSS MARGIN AVG TTM
36.12%
GROSS MARGIN AVG 3Y
29.84%
GROSS MARGIN AVG 5Y
33.38%
GROSS MARGIN AVG 10Y
36.16%
GROSS MARGIN AVG 15Y
33.19%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.40%
CURRENT VS 3Y AVG
+20.56%
CURRENT VS 5Y AVG
+7.74%
CURRENT VS 10Y AVG
-0.54%
CURRENT VS 15Y AVG
+8.37%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-13.07%
vs the sector median at left
Pacific Biosciences of California, Inc.
Market Cap
$840.18M
Gross Margin
35.97%
TTM Avg
36.12%
3Y Avg
29.84%
5Y Avg
33.38%
Market Cap
$832.12M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$838.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$826.46M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$852.84M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$854.88M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) | $840.18M | 35.97% | 36.12% | 29.84% | 33.38% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $832.12M | 92.94% | 91.25% | 45.63% | 30.42% |
| Alumis Inc. (ALMS)vs › | $843.04M | 88.23% | 42.73% | 21.36% | 21.36% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $838.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Beta Bionics, Inc. (BBNX)vs › | $826.46M | 58.31% | 55.25% | 65.77% | 65.77% |
| QuidelOrtho Corporation (QDEL)vs › | $852.84M | 44.60% | 46.45% | 50.53% | 59.76% |
| SI-BONE, Inc. (SIBN)vs › | $853.28M | 79.53% | 79.30% | 80.66% | 83.15% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $854.88M | 91.39% | 91.47% | 93.85% | 95.64% |
| Ardelyx, Inc. (ARDX)vs › | $808.55M | 93.96% | 87.19% | 88.05% | 90.06% |
| Jade Biosciences, Inc. (JBIO)vs › | $802.74M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
36.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 32.40% |
| 2026-03-31 | 34.54% |
| 2025-12-31 | 37.52% |
| 2025-09-30 | 39.20% |
| 2025-06-30 | 36.93% |
| 2025-03-31 | -3.69% |
| 2024-12-31 | 25.64% |
| 2024-09-30 | 25.03% |
| 2024-06-30 | 16.49% |
| 2024-03-31 | 29.07% |
| 2023-12-31 | 16.40% |
| 2023-09-30 | 32.15% |
| 2023-06-30 | 32.68% |
| 2023-03-31 | 25.09% |
| 2022-12-31 | 18.79% |
| 2022-09-30 | 41.93% |
| 2022-06-30 | 45.66% |
| 2022-03-31 | 42.67% |
| 2021-12-31 | 46.55% |
| 2021-09-30 | 44.04% |
| 2021-06-30 | 44.93% |
| 2021-03-31 | 44.75% |
| 2020-12-31 | 42.01% |
| 2020-09-30 | 37.02% |
| 2020-06-30 | 38.72% |
| 2020-03-31 | 48.01% |
| 2019-12-31 | 46.30% |
| 2019-09-30 | 31.55% |
| 2019-06-30 | 39.04% |
| 2019-03-31 | 31.15% |
| 2018-12-31 | 29.43% |
| 2018-09-30 | 17.58% |
| 2018-06-30 | 41.07% |
| 2018-03-31 | 37.68% |
| 2017-12-31 | 38.07% |
| 2017-09-30 | 34.94% |
| 2017-06-30 | 39.86% |
| 2017-03-31 | 35.87% |
| 2016-12-31 | 44.22% |
| 2016-09-30 | 50.31% |
| 2016-06-30 | 51.30% |
| 2016-03-31 | 49.69% |
| 2015-12-31 | 72.95% |
| 2015-09-30 | 47.07% |
| 2015-06-30 | 58.17% |
| 2015-03-31 | 33.59% |
| 2014-12-31 | 26.25% |
| 2014-09-30 | 63.82% |
| 2014-06-30 | 27.36% |
| 2014-03-31 | 22.99% |
| 2013-12-31 | 34.91% |
| 2013-09-30 | 16.72% |
| 2013-06-30 | 17.51% |
| 2013-03-31 | 16.67% |
| 2012-12-31 | 10.67% |
| 2012-09-30 | 6.84% |
| 2012-06-30 | 3.77% |
| 2012-03-31 | -1.51% |
| 2011-12-31 | 12.35% |
| 2011-09-30 | 31.64% |
| 2011-06-30 | 74.31% |
| 2011-03-31 | 100.00% |
| 2010-12-31 | 100.00% |
| 2010-09-30 | 100.00% |
| 2010-06-30 | 100.00% |
| 2010-03-31 | 100.00% |
| 2009-12-31 | 100.00% |
| 2009-09-30 | 0.00% |
